Skip to main content
. 2014 Jun 6;5(12):4060–4070. doi: 10.18632/oncotarget.2061

Figure 2. BRAF Mutation Analysis at the Case Level and Correlation with Tumor Cell Density and Event Rate in Non-Responders.

Figure 2

a. Key clinicopathological features of individual patients along with genotyping result and coded outcome data. Samples displayed as columns and arranged by disease entity, BRAF mutation status and age. b. Correlation of histiocytic infiltrate (as determined by CD1a staining) with peak-height quantification from pyrosequencing in 19 BRAF V600E mutant and 19 wild-type LCH cases. c. Stacked cumulative event rate (stable disease, recurrence, progression) in patients with multi-site or multi-system disease according to the BRAF mutation status. Abbreviations: *, multiple sites; +, central nervous system/additional organ involved; B, bone; BS, bone and skin; CR, complete response, DCS, dendritic cell sarcoma; JXG, juvenile xanthogranuloma; G, genital; GCT, granular cell tumor; L, lung; LCH, Langerhans cell histiocytosis; N, lymph node; PD, progressive disease; PR, partial response; RDD, Rosai-Dorfman, disease; S, skin; SD, stable disease; ST, soft-tissue; T, tongue; V, visceral.